# Semax (ACTH 4-10 Heptapeptide): BDNF/TrkB Upregulation, Dopaminergic-Serotonergic Neurochemistry, and Dilution Protocols

## Key Takeaways

- **Receptor Selectivity and Signaling Kinetics:** Semax (Met-Glu-His-Phe-Pro-Gly-Pro; MW 813.9 Da) operates as an ACTH(4-10) heptapeptide that dissociates central neurotrophism from MC2R-mediated adrenal steroidogenesis; the deletion of N-terminal ACTH(1-3) residues abolishes melanocortin 2 receptor binding while preserving CNS pharmacophore activity, with downstream signaling mediated through BDNF transcriptional upregulation, TrkB receptor tyrosine kinase potentiation, and consequent PI3K/Akt, MAPK/ERK, and PLCγ cascade activation governing synaptic plasticity, anti-apoptotic gene expression, and neuronal survival.
- **Dopaminergic-Serotonergic Neurochemistry:** The peptide enhances tyrosine hydroxylase activity and elevates dopamine and serotonin turnover within frontal cortex, striatal, and hippocampal circuits, while simultaneously stabilizing catecholamine metabolism under ischemia- or oxidative stress-induced challenge, integrating monoaminergic regulation with BDNF/TrkB trophic support into a dual-action neuroprotective profile lacking steroidogenic off-target liability.
- **Pharmacokinetics and Proteolytic Stability:** The C-terminal Pro-Gly-Pro cap and N-terminal methionine stabilization confer resistance to aminopeptidase and prolyl-endopeptidase hydrolysis at the Glu-His and Pro-Gly junctions, extending tissue half-life relative to native ACTH(4-10); research-grade lots are validated at >97-99% purity via RP-HPLC, MALDI-TOF mass spectrometry, and amino acid compositional analysis.
- **Volumetric Reconstitution Dynamics:** Lyophilized peptide (MW = 813.9 g/mol) is reconstituted using bacteriostatic water or sterile saline per the molarity equation (mass/volume = M × MW × 1000), with all target concentrations, diluent volumes, and syringe transfer volumes computed via the Peptide Reconstitution Calculator based on vial mass, desired molarity, and final solution volume as theoretical laboratory mathematical models.
- **Structural-Biological Basis of Selectivity:** ACTH(1-39) canonically activates the Gs-coupled MC2R in the zona fasciculata to drive corticosteroidogenesis, whereas Semax retains only the ACTH(4-10) core neurotrophic fragment, thereby preserving mnemonic and trophic pharmacology while entirely circumventing peripheral endocrine receptor engagement and downstream glucocorticoid synthesis.

> **Academic Research & Educational Disclaimer:** This scientific monograph is published exclusively for academic research, molecular biology education, laboratory investigation, and informational reference. Unapproved synthetic peptides discussed herein are intended strictly for in vitro and controlled preclinical laboratory research by qualified scientific investigators and are not intended for human consumption, direct medical self-administration, diagnostic application, or therapeutic use without direct medical supervision and valid clinical authorization. All concentration and volumetric calculations derived from the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory mathematical models based on molarity, vial mass, and diluent volume, and do not constitute clinical prescribing advice or human dosing recommendations.

## Discovery, Natural Biosynthesis, and Structural Architecture of Semax (ACTH 4-10 Heptapeptide)

### Origins in Adrenocorticotropic Hormone Fragment Biology

The **semax peptide** emerged from a focused effort within Russian neuropharmacology during the late twentieth century to dissect the structure-function relationships of adrenocorticotropic hormone (ACTH) fragments devoid of steroidogenic activity. ACTH(1-39), the full-length pituitary proopiomelanocortin (POMC) cleavage product, canonically stimulates adrenal corticosteroidogenesis via the melanocortin 2 receptor (MC2R), a Gs-coupled GPCR localized predominantly in the zona fasciculata. Systematic truncation studies revealed that the **heptapeptide core ACTH(4-10)**, corresponding to residues 4 through 10 of native ACTH, retains robust neurotrophic and mnemonic properties while completely lacking the N-terminal sequence required for melanocortin receptor activation [1, 2]. This dissociation of central nervous system (CNS) activity from peripheral endocrine liability was the conceptual cornerstone of semax design.

### Rational Design and Synthetic Pathway

Semax, the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), was generated through targeted structural modification of the ACTH(4-10) sequence. The native fragment exhibits poor metabolic stability due to rapid aminopeptidase and prolyl-endopeptidase cleavage, particularly at the Glu-His and Pro-Gly junctions. Two principal substitutions were engineered to address this liability: (1) incorporation of a **prolyl residue at the C-terminus** (replacing the native Val-Gly-Lys-Lys-Arg sequence context) and (2) deliberate **stabilization of the N-terminus** to resist aminopeptidase-mediated degradation. These modifications yielded a sequence (MEHFPGP) that retains the bioactive pharmacophore of ACTH(4-10) while conferring resistance to enzymatic hydrolysis, extending plasma and tissue half-life sufficiently for clinical and experimental utility.

Solid-phase peptide synthesis (SPPS) using Fmoc-chemistry remains the standard manufacturing route. The final heptapeptide product has a calculated monoisotopic molecular weight of approximately 813.9 Da. Quality control relies on reversed-phase HPLC, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), and amino acid analysis to confirm identity and purity, which for research and pharmaceutical-grade material must exceed 97-99%.

### Endogenous Counterparts and Biosynthesis Context

Semax is a synthetic entity; however, its **endogenous counterpart, ACTH(4-10)**, is liberated in vivo through enzymatic processing of the intact ACTH(1-39) precursor. POMC is cleaved in a tissue-specific manner by prohormone convertases (PC1/3 in the anterior pituitary, PC2 in the hypothalamus and intermediate lobe) to generate ACTH(1-39), which may be further processed into ACTH(4-10) and related fragments by extracellular and intracellular peptidases. This places semax within the larger family of POMC-derived neuropeptides that includes α-melanocyte-stimulating hormone (α-MSH), β-endorphin, and corticotropin-like intermediate peptide (CLIP), all of which contribute to neuroadaptive, analgesic, and melanocortin signaling networks.

The evolutionary conservation of the ACTH(4-10) core across vertebrate species underscores its functional significance. In rodents, primates, and humans, the MEHFPGP motif is preserved with minor tolerated substitutions, supporting the hypothesis that this fragment has been subject to selective pressure for CNS-specific bioactivity independent of adrenal function.

### Receptor Binding Profile and Signaling Architecture

A defining feature distinguishing semax (and ACTH(4-10)) from classical melanocortin ligands is the **absence of the HFRW motif** (His-Phe-Arg-Trp) required for high-affinity engagement of MC1R-MC5R. Consequently, semax does not activate canonical melanocortin receptors at physiologically relevant concentrations. Instead, its neurotrophic and neurochemical actions appear to be mediated through **non-canonical binding sites**, including a proposed melanocortin-independent receptor population in the basal forebrain and hippocampus [2]. Ligand binding assays using radiolabeled semax analogs have identified specific, saturable binding sites in rat basal forebrain membrane preparations, with affinity (Kd) in the low nanomolar range, although the molecular identity of this receptor remains incompletely characterized [2].

Downstream signaling cascades implicated in semax action include **cAMP-dependent protein kinase (PKA) activation, extracellular signal-regulated kinase (ERK1/2) phosphorylation, and phosphatidylinositol 3-kinase (PI3K)/Akt pathway engagement**, each of which converges on transcriptional programs governing synaptic plasticity and neuronal survival. The PI3K/Akt branch, in particular, is mechanistically linked to the **upregulation of brain-derived neurotrophic factor (BDNF)** and activation of its cognate receptor, the **tropomyosin receptor kinase B (TrkB)**, in hippocampal and basal forebrain circuits [1, 2].

### Structural Determinants of Biological Activity

The secondary structure of semax in aqueous solution is characterized by a **β-turn conformation centered around the Phe-Pro-Gly-Pro segment**, stabilized by intramolecular hydrogen bonding and the conformational constraint imposed by two consecutive proline residues. Nuclear magnetic resonance (NMR) spectroscopy and circular dichroism (CD) studies have demonstrated that this turn motif is critical for receptor recognition and biological activity. Structure-activity relationship (SAR) analyses indicate that:

- **Substitution of Phe6** with non-aromatic residues abolishes neurotrophic activity, consistent with a role for aromatic stacking interactions at the receptor interface.
- **Proline residues at positions 5 and 7** confer both conformational rigidity and resistance to prolyl-endopeptidase cleavage, a key determinant of in vivo half-life.
- **The N-terminal Met-Glu-His tripeptide** modulates pharmacokinetic behavior and may contribute to receptor selectivity, though its precise role in binding affinity remains an area of active investigation.

### Pharmacokinetic Considerations of the Heptapeptide Scaffold

Unlike larger peptide therapeutics, the semax heptapeptide exhibits a comparatively short plasma half-life (on the order of minutes in rodent models), yet achieves sustained CNS effects due to **rapid blood-brain barrier (BBB) penetration and intrinsic resistance to enzymatic degradation**. Intranasal administration, the predominant clinical and experimental route, exploits olfactory and trigeminal nerve pathways to bypass the BBB and deliver semax directly to the CNS parenchyma, with detectable peptide levels in cerebrospinal fluid within minutes of dosing.

This combination of structural stability, receptor specificity, and CNS bioavailability underpins the growing interest in semax as a research tool and potential therapeutic agent for cognitive enhancement, neuroprotection, and neurodegenerative disease modification.

---

**References**

[1] Dolotov OV, Karpenko EA, Inozemtseva LS et al. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." *Brain Res* (2006). DOI: https://doi.org/10.1016/j.brainres.2006.07.108

[2] Dolotov OV, Karpenko EA, Seredenina TS et al. "Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain." *J Neurochem* (2006). DOI: https://doi.org/10.1111/j.1471-4159.2006.03658.x

## Receptor Pharmacology, Binding Affinity Kinetics, and Intracellular Second Messenger Cascades

### Molecular Architecture and Receptor Recognition Domain

Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, representing a modified fragment of adrenocorticotropic hormone, ACTH(4-10). Its sequence is stabilized against aminopeptidase degradation through N-terminal succinylation, which renders the terminal amino group resistant to proteolytic cleavage while preserving the spatial orientation of the core pharmacophore. The molecular weight of Semax is approximately 863.96 Da. The peptide sequence is fundamentally devoid of classical melanocortin receptor activity, as the His-Phe-Arg-Trp tetrapartite motif required for high-affinity engagement of melanocortin receptors (MC1R through MC5R) is absent. Instead, the Met-Glu-His-Phe-Pro domain confers selective neurotrophic and neuromodulatory activity by targeting a distinct population of central nervous system binding sites.

The receptor recognition characteristics of Semax differ markedly from those of full-length ACTH. Equilibrium binding studies employing radiolabeled Semax on rat hippocampal and basal forebrain membrane preparations demonstrate that the heptapeptide associates with a high-affinity, saturable binding site that is pharmacologically distinct from melanocortin, corticotropin-releasing factor (CRF), or opioid receptors [1, 2]. Saturation isotherms yield dissociation constants (Kd) within the low nanomolar range, while Scatchard analysis reveals a single population of binding sites with a Hill coefficient approximating unity, suggesting absence of cooperative interactions. Displacement assays confirm that neither ACTH(1-39), nor ACTH(4-10), nor unrelated melanocortin fragments compete for Semax binding at physiologically relevant concentrations, reinforcing the concept of a structurally selective recognition domain within the Semax sequence.

### TrkB Engagement and BDNF Transcriptional Upregulation

The principal mechanistic basis for Semax neurotrophic activity resides in its capacity to upregulate brain-derived neurotrophic factor (BDNF) signaling. Administration of Semax in vivo produces a rapid and sustained elevation of BDNF mRNA within the rat hippocampus, an effect that is detectable within several hours of intranasal or intraperitoneal delivery and persists across a time window consistent with translational potentiation of synaptic plasticity [1, 2]. The peptide elevates BDNF protein content in the basal forebrain in a dose-dependent manner, with statistically significant increases observed at doses as low as 0.05 to 0.5 mg/kg [2].

The downstream effector of BDNF, the tropomyosin-related kinase B (TrkB) receptor, undergoes parallel regulation. Semax exposure increases trkB mRNA levels in hippocampal tissue, indicating coordinated transcriptional activation of both ligand and receptor components of the neurotrophic signaling axis [1]. This dual upregulation establishes a feed-forward amplification loop wherein elevated BDNF secretion can engage newly synthesized TrkB receptors with enhanced efficiency. TrkB activation triggers receptor dimerization and autophosphorylation of intracellular tyrosine residues within the kinase domain, generating docking sites for the adaptor proteins SH2-B, APS, and FRS-2.

### Intracellular Signaling Cascades Downstream of TrkB Engagement

Once phosphorylated, TrkB recruits and activates two principal downstream pathways: the phosphoinositide 3-kinase (PI3K)/Akt axis and the Ras/Raf/MEK/ERK cascade. The PI3K/Akt pathway is initiated through binding of the p85 regulatory subunit of PI3K to phosphorylated Y785 on TrkB, generating phosphatidylinositol (3,4,5)-trisphosphate (PIP3) at the inner leaflet of the plasma membrane. PIP3 recruits Akt via its pleckstrin homology domain, where it is phosphorylated at Thr308 and Ser473 by PDK1 and mTORC2, respectively. Activated Akt phosphorylates and inactivates glycogen synthase kinase 3β (GSK-3β), thereby liberating β-catenin and CREB from inhibitory constraint. Akt additionally suppresses pro-apoptotic signaling through phosphorylation of BAD at Ser136, stabilizing mitochondrial outer membrane integrity.

Concurrently, the Shc/Grb2/Sos adaptor complex binds phosphorylated Y490 on TrkB, initiating Ras loading with GTP and sequential activation of Raf, MEK1/2, and ERK1/2. Activated ERK1/2 translocates to the nucleus, where it phosphorylates Elk-1, CREB, and histone H3, augmenting transcription of immediate early genes and activity-regulated cytoskeletal proteins (Arc). The convergence of Akt and ERK signaling on CREB at Ser133 is particularly relevant to Semax pharmacology, as CREB-driven transcription represents the principal molecular substrate of long-term potentiation and memory consolidation. The sustained elevation of BDNF and TrkB expression produced by Semax therefore reinforces CREB phosphorylation kinetics and prolongs the window of synaptic plasticity.

A secondary messenger route that has been characterized for related ACTH fragments involves coupling through G-protein-coupled receptor (GPCR) mechanisms. While Semax itself does not activate classical melanocortin GPCRs, the peptide has been reported to elevate cAMP levels in hippocampal preparations and to enhance phospholipase C (PLC) activity, suggesting a capacity to potentiate Gs and Gq signaling in a cell-type-specific manner. Activation of Gs-coupled mechanisms would be expected to elevate cAMP, activate protein kinase A (PKA), and phosphorylate CREB at Ser133, providing a third mechanistic route for BDNF transcriptional activation independent of TrkB engagement.

### Modulation of Monoaminergic Neurochemistry

Beyond neurotrophin regulation, Semax exerts profound effects on dopaminergic and serotonergic neurotransmission. Microdialysis studies demonstrate that Semax administration increases extracellular dopamine and serotonin concentrations in the rat striatum and prefrontal cortex. The dopaminergic effect is mediated through enhanced tyrosine hydroxylase (TH) transcription and phosphorylation at Ser31 and Ser40, increasing the rate-limiting step of catecholamine biosynthesis. Semax also modulates dopamine D2 receptor expression, producing receptor sensitization that heightens postsynaptic responsiveness.

In the serotonergic domain, Semax increases tryptophan hydroxylase 2 (TPH2) expression in the raphe nuclei and elevates 5-HT release in terminal fields. The peptide concurrently modulates 5-HT1A autoreceptor sensitivity, producing a functional disinhibition of serotonergic firing. These combined actions on catecholaminergic and indoleaminergic systems establish Semax as a pleiotropic neuromodulator whose neurochemical profile extends well beyond its original designation as a melanocortin fragment analog.

### Pharmacokinetic Parameters and Intranasal Bioavailability

Semax exhibits negligible oral bioavailability due to gastric proteolysis, necessitating parenteral or intranasal administration. Intranasal delivery bypasses the blood-brain barrier through olfactory and trigeminal nerve-associated pathways, achieving direct CNS distribution within minutes. Plasma half-life following intranasal administration is approximately 4 to 6 minutes, yet CNS pharmacodynamic effects persist for several hours, consistent with the observed downstream transcriptional and translational consequences rather than direct receptor occupancy.

### Dilution Protocols and Reconstitution Standards

For experimental and clinical preparation, lyophilized Semax is reconstituted using bacteriostatic water or 0.9% sodium chloride at a working concentration of 1 mg/mL for stock solutions. Subsequent dilution into working aliquots of 100 µg/mL, 50 µg/mL, or 10 µg/mL is achieved through serial dilution in sterile saline. Peptide solutions are stored at 2 to 8 °C for short-term use (≤7 days) or at -20 °C for extended storage, with avoidance of repeated freeze-thaw cycles to prevent oxidation of the methionine residue and consequent loss of biological activity.

## Cellular and Preclinical Physiological Mechanisms in Metabolic and Regenerative Biology

### Transcriptional and Translational Modulation of the BDNF/TrkB Signaling Axis

Semax is a synthetic heptapeptide corresponding to the 4-10 fragment of adrenocorticotropic hormone, bearing the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) and a molecular weight of 863.96 Da [1, 2]. Its structural core derives from the melanocortin (MC) family of peptides, yet the 4-10 truncation confers distinct neuropharmacological properties, including resistance to proteolytic degradation and lack of adrenocortical activity. The primary mechanism of action investigated at the cellular level centers on the rapid and sustained upregulation of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor, tropomyosin receptor kinase B (TrkB), within the hippocampus and basal forebrain [1, 2].

Semax application in vivo and in primary hippocampal cultures produces a significant elevation in mature BDNF protein, the predominant ligand for TrkB, without altering the levels of the high molecular weight precursor, proBDNF [1]. This preferential post-translational or secretory regulation distinguishes Semax from general neurotrophic stimulants. The upregulation of TrkB occurs at both the transcript level, via increased mRNA expression, and at the protein level, indicating activation of a feed-forward neurotrophic loop in which Semax primes hippocampal neurons to respond more robustly to endogenous or exogenous BDNF [1, 2].

The functional consequence of TrkB enrichment is potentiation of canonical receptor signaling. TrkB dimerization triggers trans-autophosphorylation of the intracellular tyrosine kinase domain, recruiting adaptor proteins such as SHC adaptor protein 2 (SHC2), growth factor receptor-bound protein 2 (GRB2), and son of sevenless (SOS) to initiate the RAS/RAF/MEK/ERK (extracellular signal-regulated kinase) cascade. Parallel activation of phospholipase C gamma 1 (PLCγ1) generates inositol trisphosphate (IP3) and diacylglycerol (DAG), liberating intracellular calcium stores and activating protein kinase C (PKC). These cascades converge on cyclic AMP response element-binding protein (CREB), a master transcriptional regulator of genes essential for synaptic plasticity, long-term potentiation (LTP), and neuronal survival [1, 2].

### Melanocortin Receptor Subtype Selectivity and Coupling

Semax activity is intrinsically linked to its interaction with melanocortin receptors, a family of G protein-coupled receptors (GPCRs) comprising five subtypes (MC1R-MC5R). Notably, ACTH(4-10) is the minimal fragment retaining melanocortin activity, and Semax exhibits binding affinities in the nanomolar to micromolar range at MC3R and MC4R, the predominant subtypes in the central nervous system (CNS) [1]. Semax also displays detectable binding to MC5R. Sequence alignment with the endogenous ligand, alpha-melanocyte-stimulating hormone (α-MSH), reveals the conserved His-Phe-Arg-Trp tetrapeptide pharmacophore that dictates receptor binding, though Semax employs a modified Arg to Pro substitution that alters downstream signaling without abolishing receptor interaction.

MC3R and MC4R canonically couple to the Gα_s/olf family of G proteins, leading to adenylyl cyclase activation, cyclic adenosine monophosphate (cAMP) accumulation, and protein kinase A (PKA) stimulation [1]. This cAMP/PKA arm directly activates CREB, providing an upstream trigger for the observed BDNF transcriptional upregulation. Semax-mediated cAMP elevation also activates exchange protein directly activated by cAMP (Epac), which engages the Rap1/ERK pathway to further amplify neurotrophic signaling [1, 2].

Contemporary studies have demonstrated that MC4R, and to a lesser extent MC3R, exhibit functional bias and engage β-arrestin-mediated signaling pathways. Semax behavior at these GPCRs remains a topic of active investigation, with preliminary data suggesting biased agonism that favors neurotrophic transcription over canonical anorexigenic or sexual behavior modulation [1].

### Dopaminergic and Serotonergic Modulatory Activity

Semax exerts a measurable modulatory influence on monoaminergic neurotransmitter systems, particularly the dopaminergic and serotonergic pathways, which underpin its nootropic, antidepressant, and neuroprotective properties [1]. In rodent studies, Semax administration increases dopamine turnover in regions associated with executive function, motivation, and memory, including the striatum, nucleus accumbens, and prefrontal cortex. Semax also normalizes dopaminergic activity under conditions of chronic stress, oxidative insult, or dopaminergic toxicity, effectively restoring baseline dopamine levels without inducing hyperdopaminergia.

The serotonergic effects of Semax are equally significant. Semax elevates serotonin (5-HT) metabolism, shifting the metabolic ratio toward the primary metabolite 5-hydroxyindoleacetic acid (5-HIAA) without increasing 5-HT baseline concentrations, indicating enhanced serotonergic turnover [1]. This regulatory pattern is associated with augmented 5-HT release and increased synthesis rate. Such actions are particularly relevant to the antidepressant and anxiolytic properties attributed to Semax, as dysregulation of monoaminergic systems is a hallmark of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

The downstream behavioral and physiological effects of Semax on monoaminergic tone are tightly coupled to its neurotrophic activity. Because BDNF and TrkB upregulation drive the survival and differentiation of dopaminergic neurons in the substantia nigra pars compacta and serotonergic neurons in the raphe nuclei, the peptide creates a permissive biochemical environment in which monoaminergic neurons are more resilient to neurotoxic insult, oxidative stress, and inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β) [1, 2].

### Metabolic Resilience, Cytoprotection, and Regenerative Biology

Beyond neurotrophin modulation, Semax demonstrates potent cytoprotective and metabolic regulatory effects across multiple neuronal and glial cell populations. The peptide attenuates lipid peroxidation, decreases protein carbonylation, and normalizes endogenous antioxidant enzyme expression, including superoxide dismutase (SOD1, SOD2), catalase, and glutathione peroxidase [1]. By limiting oxidative stress, Semax preserves mitochondrial membrane potential, supports adenosine triphosphate (ATP) production via oxidative phosphorylation, and prevents cytochrome c release.

Semax also modulates glutamatergic neurotransmission, attenuating N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity while preserving synaptic plasticity. Through balanced regulation of NMDAR subunit expression, the peptide influences the receptor's role in learning and memory while limiting pathological calcium influx [1, 2].

In regenerative biology, Semax accelerates neurite outgrowth, promotes axonal sprouting, and facilitates synaptic remodeling following mechanical or ischemic injury. This regenerative profile is tightly linked to BDNF/TrkB signaling, as TrkB activation recruits phosphatidylinositol 3-kinase (PI3K), generating phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which activates protein kinase B (AKT) to support cytoskeletal rearrangement and growth cone formation via mammalian target of rapamycin (mTOR) and glycogen synthase kinase 3 beta (GSK-3β) [1, 2].

### Reconstitution and Dosing Considerations

Semax is conventionally supplied as a lyophilized powder in vials ranging from 10 mg to 50 mg. For experimental dosing in rodent models, peptide content and purity must be verified via high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Reconstitution protocols typically begin with the addition of a small volume of bacteriostatic water (BW) or sterile water for injection (SWFI), gradually added down the side of the vial to avoid foaming or peptide denaturation. A common 1 mg/mL working stock is prepared by adding 1 mL of diluent to a 10 mg vial, with gentle swirling to ensure homogeneity.

For intranasal dosing or intraperitoneal injection in animal studies, further dilutions can be prepared in sterile saline to achieve target doses (commonly 0.1 mg/kg to 1.0 mg/kg body weight). It is important to note that Semax solutions are stable for several weeks when refrigerated at 2-8 °C, although single-use aliquots are recommended to prevent repeated freeze-thaw cycles and microbial contamination. For translational or clinical applications, quality-controlled manufacturing under Good Manufacturing Practice (GMP) standards is essential to ensure batch-to-batch consistency and absence of endotoxin contamination.

## Pharmacokinetics, Proteolytic Degradation Pathways, and Chemical Modification Stability

### Molecular Architecture and Physicochemical Properties Relevant to Stability

Semax is a synthetic heptapeptide corresponding to the sequence of adrenocorticotropin (ACTH(4-10)), with the primary structure Met-Glu-His-Phe-Pro-Gly-Pro. The molecular weight is approximately 879.0 g/mol, with a theoretical isoelectric point near neutrality due to the balance between the N-terminal methionine amine, the glutamate side-chain carboxyl, and the histidine imidazole. The native ACTH(4-10) fragment is rapidly cleared from circulation by nonspecific exopeptidases and endopeptidases; to extend its biological half-life while preserving the neurotrophic core, the C-terminal Pro-Gly-Pro tail was appended, mimicking a "proline-rich shield" that confers partial resistance to carboxypeptidase and dipeptidyl peptidase activity [1, 2]. The N-terminus remains a free α-amino group on methionine, and the C-terminus is an unmodified carboxylic acid. There is no cyclization, no D-amino acid substitution, and no N-terminal acetylation in the clinical peptide used in Russian Federation pharmacopoeia. As a result, the molecule is highly water-soluble and behaves as a flexible linear chain in solution, with conformational sampling biased toward polyproline II-like geometries in the C-terminal region.

### Routes of Administration and Systemic Absorption

Semax is administered exclusively by the intranasal route in human and animal protocols, bypassing the blood-brain barrier via the olfactory and trigeminal perineural pathways that deliver peptides directly into the cerebrospinal fluid and olfactory bulb. Intranasal dosing in rats and humans achieves peak cerebrospinal fluid concentrations within 15 to 30 minutes, with measurable immunoreactivity persisting in the hippocampus, basal forebrain, and frontal cortex for several hours despite extremely low or undetectable plasma concentrations [1, 2]. The peptide is delivered to the brain parenchyma by paracellular transport along the olfactory nerve, by transcellular uptake at the respiratory epithelium, and by receptor-mediated endocytosis involving putative peptide transporter systems. The very low systemic bioavailability after intranasal administration is, paradoxically, a pharmacokinetic advantage for a neurotrophic agent: peripheral proteolysis by hepatic and renal peptidases is minimized, and the fraction that does reach the circulation is rapidly degraded, limiting off-target endocrine activity that would otherwise be expected from an ACTH-derived sequence.

### Proteolytic Susceptibility and Degradation Pathways

In vitro incubation of Semax with rat plasma or brain homogenates reveals a degradation half-life in the order of minutes, with cleavage events concentrated at three peptide bonds: Glu-His, His-Phe, and Phe-Pro. Aminopeptidase M and dipeptidyl peptidase IV can liberate Met-Glu and Glu-His dipeptides, while neprilysin and angiotensin-converting enzyme have been implicated in cleavage of the Phe-Pro bond [1]. The C-terminal Pro-Gly-Pro extension does not completely abolish carboxypeptidase P activity but reduces the rate of C-terminal trimming by approximately an order of magnitude relative to native ACTH(4-10). Importantly, the metabolic fragments that are generated, particularly the central tetrapeptide His-Phe-Pro-Gly-Pro, retain partial neurotrophic activity in hippocampal slice preparations, suggesting that Semax may function in part as a "metabonotropic" prodrug with active degradation products.

### Blood-Brain Barrier Penetration and Intracerebral Pharmacokinetics

Microdialysis studies in rat hippocampus demonstrate that after intranasal administration of 0.05 to 0.5 mg/kg Semax, peptide-derived immunoreactivity rises two- to four-fold above baseline within 30 minutes and remains elevated for at least 120 minutes. Brain-region distribution is heterogeneous, with the highest concentrations recovered from the olfactory bulb, hippocampus, basal forebrain, and frontal cortex, regions that correspond to the anatomical sites of Semax's neurotrophin and monoamine-modulating activity [1, 2]. Cerebrospinal fluid concentrations after intranasal delivery in humans reach the low nanomolar range, sufficient to engage high-affinity neurotrophic receptors and to trigger downstream cAMP response element-binding protein (CREB) phosphorylation.

### Mechanisms Underlying the Extended Intracerebral Half-Life

The prolonged central action of Semax relative to its short plasma half-life is attributable to four complementary mechanisms. First, intranasal delivery bypasses first-pass hepatic metabolism. Second, the proline-rich C-terminus impedes carboxypeptidase degradation. Third, the peptide binds saturably to as-yet incompletely characterized binding sites in the basal forebrain and hippocampus, effectively buffering free peptide and slowing dissociation into the extracellular proteolytic pool; Dolotov and colleagues demonstrated specific and saturable binding of radiolabeled Semax in rat basal forebrain homogenates with an apparent affinity in the low nanomolar range [2]. Fourth, once Semax engages the neurotrophin signaling cascade and upregulates BDNF and TrkB expression, the biological effects persist long after the peptide itself is cleared, producing a pharmacological half-life in functional terms of many hours rather than minutes [1, 2].

### Chemical Modifications and Stability-Enhancing Strategies

Because the unmodified peptide remains vulnerable to rapid proteolysis, several research-grade modifications have been explored to improve stability. C-terminal amidation removes the negatively charged carboxylate and confers resistance to carboxypeptidases, modestly increasing half-life in plasma while preserving receptor engagement. Substitution of the methionine residue with norleucine prevents oxidation of the thioether side chain during storage, an important consideration for clinical formulations. Incorporation of D-proline at position 7 stabilizes the C-terminus against proline-specific peptidases. Cyclization through a lactam bridge between the glutamate γ-carboxyl and the N-terminal amine yields a constrained analog with substantially improved plasma stability, although such modifications alter the conformational ensemble and may change receptor selectivity. PEGylation at the N-terminus has been explored preclinically to extend plasma residence time but is not used in current clinical Semax preparations because the therapeutic target is the central nervous system and prolonged peripheral exposure is undesirable.

### Dilution Protocols, Storage, and Analytical Considerations

For research applications, Semax is commonly supplied as a lyophilized trifluoroacetate salt at purities exceeding 98 percent by reverse-phase HPLC and mass spectrometry. Stock solutions are typically prepared in sterile, nuclease- and protease-free water at 1 to 10 mg/mL, with brief sonication facilitating dissolution of the otherwise fluffy lyophilized pellet. For intranasal animal dosing, working dilutions are prepared in physiological saline (0.9 percent NaCl) to final concentrations of 0.05 to 1 mg/mL, and aliquots are stored at -20 °C or -80 °C to prevent repeated freeze-thaw degradation. Long-term storage of reconstituted peptide at 4 °C for more than 72 hours is discouraged because of bacterial proliferation and progressive oxidation of the methionine residue. Analytical verification of stock concentration can be performed by UV absorbance at 280 nm using the molar extinction coefficient derived from the single phenylalanine and histidine residues, or more accurately by quantitative amino acid analysis. Peptide integrity should be confirmed periodically by analytical reverse-phase HPLC on a C18 column with an acetonitrile gradient in 0.1 percent trifluoroacetic acid; degradation is signaled by the emergence of earlier-eluting hydrophilic fragments corresponding to truncated forms. For cell culture work, Semax is diluted into serum-containing medium at 10 to 100 nM final concentration, with attention to avoid adsorption losses on polystyrene or low-binding tubes by pre-coating plasticware with 0.1 percent bovine serum albumin or by using siliconized tubes.

### Integration of Pharmacokinetics with Pharmacodynamic Action

The aggregate pharmacokinetic profile of Semax, consisting of rapid central access after intranasal delivery, moderate resistance to proteolysis conferred by the proline-rich C-terminus, specific binding within neurotrophin-responsive brain regions, and downstream induction of BDNF and TrkB [1, 2], creates a pharmacological profile in which brief peptide exposure initiates a sustained neurotrophic program. This profile is well matched to therapeutic indications requiring once- or twice-daily intranasal dosing, including cognitive support, ischemic stroke recovery, and pediatric attention and memory disorders.

## Lyophilized Peptide Chemistry, Solvent Reconstitution Protocols, and Temperature Storage

### Primary Structure and Physicochemical Profile of Semax

Semax is a synthetic heptapeptide corresponding to the sequence of adrenocorticotropic hormone ACTH(4-10), specifically Met-Glu-His-Phe-Pro-Gly-Pro. The primary structure incorporates a proline residue at the C-terminus (position 7), which serves as a substrate for prolyl endopeptidase and confers partial resistance to enzymatic degradation, extending its biological half-life relative to the native ACTH(4-10) fragment [1]. The theoretical molecular weight of the free base form is approximately 813.9 g/mol, with a molecular formula of C37H51N9O10S. The peptide contains a single methionine residue at the N-terminus, which is susceptible to oxidation during prolonged storage, especially in the presence of residual moisture or trace metal contaminants. This methionine residue demands careful handling and appropriate storage conditions to preserve the sulfhydryl group in its reduced thioether state.

Semax is commercially supplied as a lyophilized (freeze-dried) powder, typically as the acetate salt, packaged in sterile 2 mL or 5 mL glass vials under vacuum or inert nitrogen atmosphere. The lyophilization matrix generally consists of mannitol or a combination of mannitol and sodium chloride, which serves as a bulking agent to preserve the structural cake and facilitate rapid dissolution upon reconstitution. The lyophilized form offers significant advantages for long-term stability, as the removal of water greatly suppresses hydrolytic cleavage of peptide bonds and minimizes molecular mobility that could otherwise lead to degradation.

### Solvent Selection for Reconstitution

The reconstitution of lyophilized semax peptide requires careful selection of the solvent vehicle to ensure complete solubilization and preservation of biological activity. Because the peptide exhibits a net charge that depends on solution pH, the choice of diluent influences its dissolution kinetics. Three primary solvent systems are utilized in experimental and research contexts:

1. **Sterile Bacteriostatic Water (0.9% benzyl alcohol preserved water)**: This is the most common diluent for nasal spray applications or short-term in vitro use. The presence of 0.9% benzyl alcohol provides bacteriostatic activity for multi-dose vials, though it should be noted that benzyl alcohol can induce cellular stress responses in certain primary neuronal cultures at elevated concentrations.
2. **Sterile Water for Injection (WFI)**: Preferred for immediate use preparations or for administration routes where preservatives are contraindicated, such as certain in vivo animal research protocols. WFI lacks antimicrobial preservatives, so reconstituted solutions must be used promptly or stored under refrigeration.
3. **Phosphate-Buffered Saline (PBS), pH 7.4**: Useful when the reconstituted peptide is destined for cell culture applications or receptor binding assays, because PBS maintains physiological ionic strength and osmolarity, thereby preventing osmotic shock in cultured neurons and preserving downstream BDNF/TrkB signaling assays [1, 2].

When reconstituting, the diluent should be injected slowly down the inside wall of the vial rather than directly onto the lyophilized cake. This minimizes foaming and turbulence that can denature peptide conformers. Gentle swirling or inversion is recommended over vigorous vortexing, as mechanical agitation may introduce shear forces that disrupt the secondary structure of the peptide. Reconstitution to a typical working concentration of 1 mg/mL is readily achieved, though more concentrated stock solutions (up to 10 mg/mL) are feasible if the peptide is first allowed to equilibrate with the solvent for several minutes.

### Bacteriostatic Considerations and Contamination Prevention

Because semax is supplied in multi-dose research vials intended for repeated withdrawals, aseptic technique is mandatory. Each withdrawal should be performed using a fresh sterile syringe and needle to avoid introducing microbial contaminants. The reconstituted peptide solution lacks broad-spectrum antimicrobial protection when diluted in WFI or PBS, which is a significant factor in determining its usable shelf life. Filtration through a 0.22 µm low protein-binding membrane filter (such as a polyvinylidene fluoride or polyethersulfone membrane) is recommended when sterility is paramount, particularly for cell culture work. It should be noted that filters with high protein affinity, such as certain cellulose acetate or nylon membranes, may bind semax nonspecifically and reduce the recoverable concentration.

### Temperature-Dependent Degradation Kinetics

The integrity of the **semax peptide** in lyophilized form depends critically on storage temperature. Manufacturers typically recommend storage at 2°C to 8°C for short-term use (up to several weeks) and -20°C for long-term archival. At -20°C, the lyophilized peptide remains stable for periods of at least 12 to 24 months. Storage at -80°C is advisable for periods exceeding 24 months or when the highest degree of chemical fidelity must be maintained, particularly for sensitive downstream assays measuring BDNF expression or TrkB receptor activation [1, 2].

Repeated freeze-thaw cycles are detrimental to the structural integrity of the peptide. Each cycle promotes the formation of ice crystals that can mechanically stress the matrix and expose the peptide to residual moisture, accelerating oxidation of the methionine residue and potential aggregation. To mitigate this, single-use aliquots should be prepared immediately after initial reconstitution, with each aliquot intended for a single experimental session. Working solutions should be thawed on ice or at 4°C and never at ambient temperature or with the aid of a heating block, as elevated temperatures accelerate both oxidation and hydrolytic degradation.

### Storage of Reconstituted Solutions

Reconstituted semax peptide solutions are markedly less stable than the lyophilized form. At 4°C, reconstituted solutions remain chemically stable for approximately 7 to 14 days, depending on the concentration and the presence of antioxidants. The addition of 0.1% human serum albumin or a stabilizing carrier protein can prolong the usable window by reducing adsorption losses to the vial surface and minimizing aggregation. Storage at -20°C extends the shelf life of reconstituted aliquots to approximately 30 to 60 days, although long-term storage of reconstituted peptide is generally discouraged in favor of storing concentrated lyophilized stock.

### Chemical Stability and Analytical Verification

Analytical confirmation of semax integrity can be performed via reverse-phase high-performance liquid chromatography (RP-HPLC) with detection at 214 nm or 220 nm, providing information on both purity and the presence of degradation products such as methionine-oxidized species or truncated fragments. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption/ionization (MALDI), yields the intact molecular ion at m/z ~813.9 [M+H]+, allowing confirmation of sequence fidelity. Biological activity validation through BDNF ELISA or TrkB phosphorylation assays in cultured hippocampal neurons further confirms that the reconstituted peptide retains its neurotrophic signaling properties [1, 2].

### Practical Recommendations for Experimental Use

For investigators examining the dopaminergic-serotonergic neurochemistry and BDNF/TrkB upregulation properties of semax, the following protocol framework is suggested: reconstitute the lyophilized peptide in sterile WFI or PBS at a stock concentration of 1 mg/mL, aliquot into single-use polypropylene tubes, store at -20°C, and thaw immediately prior to application. This approach preserves the heptapeptide's capacity to bind melanocortin receptor subtypes and to upregulate BDNF protein levels in the rat basal forebrain, as previously documented in controlled studies [1, 2]. Adherence to these reconstitution and storage protocols ensures reproducibility and experimental validity across downstream neurochemical, electrophysiological, and behavioral assays.

## Syringe Calibration (U-100 & U-40), Volumetric Dilution Math, and Interactive Peptide Calculator Integration

### Volumetric Fundamentals of Peptide Reconstitution

Accurate dosing of **Semax (ACTH 4-10 heptapeptide)** requires rigorous volumetric control because the lyophilized powder is typically supplied in microgram quantities (often 30 mg vials) and intended doses are in the 250 to 1000 mcg range. The underlying principle of reconstitution relies on the relationship between mass (mg), concentration (mg/mL), and volume (mL), where V = m / C. For a 30 mg vial of Semax reconstituted with 3 mL of bacteriostatic water, the resultant stock concentration is 10 mg/mL. Because therapeutic doses are vastly lower, serial dilution is required to bridge the gap between stock and injectable volumes that can be accurately handled by standard insulin syringes [1, 2].

### Syringe Calibration Architecture: U-100 versus U-40

Insulin syringes are classified by their "units per milliliter" rating, which dictates how the physical volume of the barrel is partitioned. A **U-100 syringe** is engineered such that 100 units equal exactly 1 mL; therefore, each unit corresponds to 0.01 mL or 10 microliters. A **U-40 syringe**, historically used for veterinary insulin, has 40 units per milliliter, meaning 1 unit equals 0.025 mL or 25 microliters. The U-100 format is the standard for human use and offers finer volumetric resolution per unit, which is advantageous when drawing very small doses of diluted peptide solutions.

If a Semax solution is reconstituted at 1 mg/mL (1000 mcg/mL), then 10 units on a U-100 syringe deliver 100 mcg, whereas 10 units on a U-40 syringe deliver 250 mcg. This fourfold discrepancy is one of the most common sources of dosing error. Researchers and self-experimenters must confirm the syringe calibration before every injection, because the visual difference between U-40 and U-100 barrels can be subtle; the barrel of a U-40 syringe is typically marked with a red or orange cap, while U-100 syringes use an orange cap for 50 unit barrels and red for 100 unit barrels.

### Stepwise Dilution Mathematics

Because Semax is dosed in the hundreds of micrograms range, a single-vial reconstitution at 1 mg/mL still requires drawing volumes of 25 to 100 units on a U-100 syringe. To improve accuracy, a two-step dilution is employed. Starting with 30 mg of lyophilized Semax, the researcher adds 3 mL of diluent to produce 10 mg/mL. From this stock, 0.3 mL (30 units on a U-100 syringe) is transferred into a second sterile vial containing 2.7 mL of bacteriostatic water, yielding a final concentration of 1 mg/mL (1000 mcg/mL). At this concentration, 10 units on a U-100 syringe yield exactly 100 mcg, and 25 units yield 250 mcg, aligning precisely with typical nootropic dosing protocols informed by the BDNF/TrkB upregulation literature [1, 2].

For even lower concentrations, a third dilution can be performed: 0.5 mL of the 1 mg/mL solution added to 4.5 mL of diluent produces 0.1 mg/mL (100 mcg/mL). At this dilution, 10 units on a U-100 syringe deliver only 10 mcg, allowing for sub-100 mcg dosing without fractional syringe readings. This stepwise approach minimizes compounded pipetting error and preserves peptide integrity, as repeated freeze-thaw cycles can degrade the linear heptapeptide and reduce its neurotrophic activity [1].

### Interactive Peptide Calculator Integration

Manual calculation introduces transcription errors, particularly when researchers alternate between metric and insulin unit conventions. An **interactive peptide calculator** eliminates this risk by accepting inputs in mg, mL, mcg, and units and automatically resolving the cross-dimensional arithmetic. The calculator should ingest the following parameters: peptide mass per vial, diluent volume, desired dose in mcg, and syringe type (U-100 or U-40). It then outputs the exact number of units to draw.

For Semax, a typical calculator workflow proceeds as follows. The user enters vial mass (e.g., 30 mg) and diluent volume (e.g., 3 mL), producing a stock concentration of 10 mg/mL. If the target dose is 500 mcg, the calculator returns 5 units on a U-100 syringe or 12.5 units on a U-40 syringe. If the user selects a two-step dilution to 1 mg/mL, the same 500 mcg dose requires 50 units on a U-100 syringe, a volume that exceeds the capacity of a standard 0.5 mL (50 unit) insulin syringe and therefore signals the need for either a 1 mL syringe or a further dilution step.

A well-designed calculator also accounts for dead volume, the residual liquid retained in syringe hubs and vial stoppers after aspiration. For standard 29 to 31 gauge insulin syringes, dead volume is approximately 0.005 to 0.01 mL. While negligible at high concentrations, this loss becomes proportionally significant at the 0.1 mg/mL dilution tier, where 0.01 mL of dead volume corresponds to 1 mcg of Semax, roughly 1% of a 100 mcg dose.

### Reconciling Volumetric Precision with Peptide Stability

Semax is a linear heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) lacking disulfide bonds, which makes it susceptible to hydrolysis and oxidation. Reconstituted solutions are stable for approximately 14 to 30 days when refrigerated at 2 to 8 degrees Celsius, but adsorption to plastic surfaces becomes a concern at very low concentrations. Polypropylene syringes and vials are preferred over polystyrene, and silicone oil lubrication in insulin syringes can strip peptide from solution at sub-micromolar concentrations [1, 2].

To mitigate adsorption, diluents should include 0.1% to 0.5% human serum albumin or an equivalent carrier protein when preparing low-concentration Semax solutions for in vivo administration. The calculator should therefore include a "carrier protein recommended" flag when the calculated peptide concentration falls below 10 mcg/mL, a threshold below which surface adsorption losses can exceed 10% of the total peptide mass.

### Practical Dosing Matrix for Semax

Based on the BDNF and TrkB expression studies in rat hippocampus and basal forebrain, effective doses in rodent models typically range from 0.05 to 0.5 mg/kg [1, 2]. Translating this to a 70 kg human via allometric scaling yields a range of approximately 0.6 to 6 mg total dose, though empirical self-experimenter reports cluster around 250 to 1000 mcg per intranasal or subcutaneous administration. Using the two-step dilution protocol described above, these doses correspond to 25 to 100 units on a U-100 syringe from a 1 mg/mL working solution, a volume range that sits comfortably within the readable graduations of a standard 1 mL (100 unit) insulin syringe.

The integration of an interactive calculator into the reconstitution workflow ensures that the bioactivity reported in the foundational Semax literature, particularly the upregulation of BDNF protein in the basal forebrain and TrkB mRNA in the hippocampus, is preserved through precise dosing rather than lost to volumetric imprecision [1, 2]. By standardizing the calibration of U-100 and U-40 syringes, applying stepwise dilution mathematics, and leveraging calculator-driven unit conversion, researchers can reliably deliver Semax at the concentrations required to engage its neurotrophic and neuromodulatory mechanisms.


## Practical Applications and Research Context

The peptide biochemistry and pharmacology described in this monograph reflects findings from preclinical models, in vitro assays, and early-phase clinical investigations. Several important limitations and evidence gaps apply to this body of literature:

**Evidence-Quality Boundaries:** Many mechanistic findings derive from rodent models, cell-line experiments, or small-cohort human studies. Extrapolation to human physiology should be made with caution, as dose-response relationships, receptor affinities, and pharmacokinetic parameters may differ substantially between species and experimental conditions.

**Regulatory and Approval Status:** The research peptides discussed in this monograph are not approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent regulatory bodies for unsupervised human use unless specifically noted otherwise. Investigators should consult current FDA, DEA, and institutional review board (IRB) guidance before initiating any research protocol.

**Reconstitution and Dosing Uncertainty:** Concentration calculations provided via the [Peptide Reconstitution Calculator](/tools/peptide-calculator) represent theoretical laboratory models based on mass-volume-molarity relationships. Batch purity, lyophilization efficiency, and excipient composition affect actual effective concentration in research-grade peptide preparations.

**Professional Supervision:** Any application of peptide science beyond controlled in vitro and preclinical laboratory settings requires direct oversight from appropriately licensed physicians, clinical pharmacologists, or veterinary professionals. The [knowledge base](/knowledge) on this site is designed to support scientific literacy, not to replace professional medical or veterinary judgment.

**Ongoing Research Landscape:** The peptide pharmacology field is rapidly evolving. Investigators are encouraged to consult primary literature, clinical trial registries (ClinicalTrials.gov), and regulatory guidance documents for the most current evidence and approval status.


## References

[1] Dolotov OV, Karpenko EA, Inozemtseva LS et al. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.". *Brain Res*, 2006. [DOI: https://doi.org/10.1016/j.brainres.2006.07.108](https://doi.org/10.1016/j.brainres.2006.07.108)

[2] Dolotov OV, Karpenko EA, Seredenina TS et al. "Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.". *J Neurochem*, 2006. [DOI: https://doi.org/10.1111/j.1471-4159.2006.03658.x](https://doi.org/10.1111/j.1471-4159.2006.03658.x)

## Related Articles

Explore additional peer-reviewed peptide research monographs in the knowledge base:

- [Selank: Tuftsin Analog & GABA Modulation](/knowledge/molecular-biology/selank-tuftsin-analog-anxiolytic-gaba-neurochemistry)
- [Cerebrolysin: Neurotrophic Peptide Complex](/knowledge/molecular-biology/cerebrolysin-neurotrophic-peptide-complex-neurogenesis-neuroprotection)
- [BPC-157: Multi-System Tissue Repair Peptide](/knowledge/molecular-biology/bpc-157-body-protection-compound-molecular-mechanisms-tissue-repair)
- [GHK-Cu: Transcriptomic & Neuroprotective Effects](/knowledge/molecular-biology/ghk-cu-copper-tripeptide-gene-modulation-tissue-remodeling)
- [Peptide Reconstitution Calculator](/tools/peptide-calculator) - Calculate exact reconstitution volumes, syringe tick marks, and per-dose injection quantities